Evidence map›Paper›PMID 24586911›Full record

ArticlePloS one2014

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.

Lisa L Ross, Joseph Horton, Samiul Hasan, James R Brown, Daniel Murphy, Edwin DeJesus, Martin Potter, Anthony LaMarca, Ivan Melendez-Rivera, Douglas Ward and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00440947 (See Detailed Description), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00440947 phase3completednot on this map

See Detailed Description

TypeinterventionalSponsorViiV HealthcareRan2007 to 2010Enrolled515ConditionsInfection, Human Immunodeficiency Virus I, HIV InfectionArmsAbacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r), Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks.Journal of acquired immune deficiency syndromes (1999) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Lisa L RossViiV HealthCare, Research Triangle Park, North Carolina, United States of America.
Joseph HortonGlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
Samiul HasanGlaxoSmithKline, Stevenage, United Kingdom.
James R BrownGlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
Daniel MurphyClinique Medicale L'Actuel, Montreal, QC, Canada.
Edwin DeJesusOrlando Immunology Center, Orlando, Florida, United States of America.
Martin PotterMcGill University Health Centre, Montreal, QC, Canada.
Anthony LaMarcaTherafirst Medical Center, Ft Lauderdale, Florida, United States of America.
Ivan Melendez-RiveraCentro Ararat, Ponce, Puerto Rico.
Douglas WardDupont Circle Physicians Group, Washington, DC, United States of America.
Jonathon UyAmicus Therapeutics, Cranbury, New Jersey, United States of America.
Mark S ShaeferViiV HealthCare, Research Triangle Park, North Carolina, United States of America.
GlaxoSmithKline (United States) · USAmicus Therapeutics (United States) · USGlaxoSmithKline (United Kingdom) · GBMcGill University Health Centre · CAOrlando Immunology Center · USTherafirst Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant public health concern. In-depth phylogenetic analyses of viral sequences obtained in the screening phase from antiretroviral-naïve HIV-infected patients seeking enrollment in EPZ108859, a large open-label study in the USA, Canada and Puerto Rico (ClinicalTrials.gov NCT00440947) were examined for insights into the roles of drug resistance and epidemiological factors that could impact disease dissemination. Viral transmission clusters (VTCs) were initially predicted from a phylogenetic analysis of population level HIV-1 pol sequences obtained from 690 antiretroviral-naïve subjects in 2007. Subsequently, the predicted VTCs were tested for robustness by ultra deep sequencing (UDS) using pyrosequencing technology and further phylogenetic analyses. The demographic characteristics of clustered and non-clustered subjects were then compared. From 690 subjects, 69 were assigned to 1 of 30 VTCs, each containing 2 to 5 subjects. Race composition of VTCs were significantly more likely to be white (72% vs. 60%; p = 0.04). VTCs had fewer reverse transcriptase and major PI resistance mutations (9% vs. 24%; p = 0.002) than non-clustered sequences. Both men-who-have-sex-with-men (MSM) (68% vs. 48%; p = 0.001) and Canadians (29% vs. 14%; p = 0.03) were significantly more frequent in VTCs than non-clustered sequences. Of the 515 subjects who initiated antiretroviral therapy, 33 experienced confirmed virologic failure through 144 weeks while only 3/33 were from VTCs. Fewer VTCs subjects (as compared to those with non-clustering virus) had HIV-1 with resistance-associated mutations or experienced virologic failure during the course of the study. Our analysis shows specific geographical and drug resistance trends that correlate well with transmission clusters defined by HIV sequences of similarity. Furthermore, our study demonstrates the utility of molecular and epidemiological analysis of VTCs for identifying population-specific risks associated with HIV-1 transmission and developing effective local healthcare strategies.

Indexed as

Antiretroviral Therapy, Highly ActivePhylogenyAdultFemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansMaleMolecular Sequence DataMutationNorth AmericaPrognosis

Identifiers

PMID24586911
PMCPMC3935917
OpenAlexW1999824035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.